Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

Caribou Biosciences (NASDAQ:CRBU – Get Free Report) had its price target dropped by equities researchers at Bank of America from $13.00 to $11.00 in a research report issued to clients and investors ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...

Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today provided its strategic ...

TOPLINE: Sjögren disease (SjD) presents three distinct phenotypes ― B-cell active with low symptom burden, high systemic ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...

ADC Therapeutics (ADCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns ...